Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open-Label, Prospective, Randomized Pilot Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Joo Yong | - |
dc.contributor.author | Kang, Dong Hyuk | - |
dc.contributor.author | Park, Sung Yul | - |
dc.contributor.author | Lee, Seung Wook | - |
dc.contributor.author | Kim, Yong Tae | - |
dc.contributor.author | Choi, Hong Yong | - |
dc.contributor.author | Moon, Hong Sang | - |
dc.date.accessioned | 2022-07-16T17:11:08Z | - |
dc.date.available | 2022-07-16T17:11:08Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2012-01 | - |
dc.identifier.issn | 1757-5664 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/166578 | - |
dc.description.abstract | Objective: This study was conducted to examine the effect of discontinuing tamsulosin in patients with benign prostatic hyperplasia who had been receiving combination therapy with tamsulosin and dutasteride. Methods: The study sample consisted of 108 men with benign prostatic hyperplasia and lower urinary tract symptoms who visited our urology clinics between April 2008 and December 2010. All were assessed using the International Prostate Symptom Score (IPSS). The patients had IPSS of 8-19 and prostate volumes >= 25 mL by transrectal ultrasonography. They were put on tamsulosin and dutasteride, and the efficacy of this regimen was assessed every 12 weeks. After 48 weeks, patients were divided at random into a group continuing to take the same drug combination (group 1) and a group taking only dutasteride 0.5 mg (group 2). Results: Sixty-nine of the original 108 patients completed the study, 36 (52%) in group 1 and 33 (48%) in group 2. The mean age of all patients was 67.96 +/- 7.88 years and mean prostatic volume was 40.45 +/- 12.81 mL. Mean prostate-specific antigen was 3.31 (0.4-9.9) ng/mL at the outset. The IPSS scores of the two groups at first visit, 48 and 72 weeks were, respectively, 14.69 versus 15.85 (P = 0.322), 12.08 versus 12.85 (P = 0.582) and 10.89 versus 11.06 (P = 0.897.) There was a statistically significant difference between the baseline and 72-week IPSS scores in both groups (group 1: P < 0.001, group 2: P < 0.001). Conclusion: In patients with moderate IPSS, discontinuing tamsulosin after 48 weeks of combined tamsulosin and dutasteride therapy has no significant effect on outcome. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open-Label, Prospective, Randomized Pilot Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Seung Wook | - |
dc.contributor.affiliatedAuthor | Kim, Yong Tae | - |
dc.contributor.affiliatedAuthor | Choi, Hong Yong | - |
dc.contributor.affiliatedAuthor | Moon, Hong Sang | - |
dc.identifier.doi | 10.1111/j.1757-5672.2011.00109.x | - |
dc.identifier.scopusid | 2-s2.0-84855449629 | - |
dc.identifier.wosid | 000298838900008 | - |
dc.identifier.bibliographicCitation | LUTS-LOWER URINARY TRACT SYMPTOMS, v.4, no.1, pp.35 - 40 | - |
dc.relation.isPartOf | LUTS-LOWER URINARY TRACT SYMPTOMS | - |
dc.citation.title | LUTS-LOWER URINARY TRACT SYMPTOMS | - |
dc.citation.volume | 4 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 35 | - |
dc.citation.endPage | 40 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | URINARY-TRACT SYMPTOMS | - |
dc.subject.keywordPlus | 5-ALPHA-REDUCTASE INHIBITOR DUTASTERIDE | - |
dc.subject.keywordPlus | MEDICAL THERAPY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | OPTIONS | - |
dc.subject.keywordPlus | VOLUME | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | dutasteride | - |
dc.subject.keywordAuthor | prostatic hyperplasia | - |
dc.subject.keywordAuthor | tamsulosin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.